Pancreatic Cancer Research

ResearcherIowa State UniversityActive in the last 2 years

Joyce C. Solheim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6313-8213; OpenAlex author ID A5086505077; NIH RePORTER profile ID 1864089. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 9)
Trials
0
Grants
4
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 1 grant · 2012: 1 paper · 2013: 1 grant · 2014: 1 grant · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper, 1 grant · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 16

  1. A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. Co-author DOI 10.1016/j.actbio.2026.04.026↗
  2. Correction: Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal … Last author DOI 10.1007/s12026-023-09442-9↗
  3. Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells. Last author DOI 10.3390/ijms25063211↗
  4. Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth facto… Last author DOI 10.1007/s12026-022-09262-3↗
  5. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Co-author DOI 10.1016/j.semcancer.2022.08.009↗
  6. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. Last author DOI 10.1371/journal.pone.0273518↗
  7. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Co-author DOI 10.7150/thno.64805↗
  8. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. Co-author DOI 10.1002/jbm.a.37080↗
  9. Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-021-01800-4↗
  10. Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic… Last author DOI 10.3390/cancers13071535↗
  11. HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. Last author DOI 10.1016/j.yexcr.2020.111960↗
  12. Beta 2-microglobulin regulates amyloid precursor-like protein 2 expression and the migration of pancreatic cancer cells. Last author DOI 10.1080/15384047.2019.1580414↗
  13. Emerging trends in the immunotherapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.12.012↗
  14. Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. Last author DOI 10.18632/oncotarget.2990↗
  15. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Co-author DOI 10.18632/oncotarget.5935↗
  16. Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells. Last author DOI 10.3892/ijo.2012.1553↗

Grants 4

  1. New Strategy for Pancreatic Cancer Therapy R21CA223429↗
  2. Flt3L Treatment of Pancreatic Cancer R03CA173223↗
  3. Effect of Beta-secretase Inhibitors on Pancreatic Cancer Cells R03CA169953↗
  4. PROJECT 4:MECHANISMS FACILITATING GROWTH & METASTASIS OF PANCREATIC CANCER P20RR018759↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alaina C. Larson · 6 shared papers, 2021–2024 · strength 1.12
  2. Surinder K. Batra · 8 shared papers, 2015–2026 · strength 1.04
  3. Shelby M. Knoche · 5 shared papers, 2021–2024 · strength 0.94
  4. Maneesh Jain · 5 shared papers, 2018–2026 · strength 0.74
  5. Sushil Kumar K · 5 shared papers, 2018–2022 · strength 0.64
  6. Balaji Narasimhan · 4 shared papers, 2018–2026 · strength 0.56
  7. Shailendra Kumar Gautam · 4 shared papers, 2018–2026 · strength 0.56
  8. Luman Liu · 3 shared papers, 2021–2026 · strength 0.49
  9. Brittany J. Poelaert · 4 shared papers, 2018–2022 · strength 0.44
  10. Bailee H. Sliker · 3 shared papers, 2019–2022 · strength 0.39
  11. Aliasger K Salem · 2 shared papers, 2022–2026 · strength 0.37
  12. Kasturi Banerjee · 2 shared papers, 2018–2026 · strength 0.31
  13. H. Carlo Maurer · 2 shared papers, 2020–2021 · strength 0.24
  14. Kenneth P. Olive · 2 shared papers, 2020–2021 · strength 0.24
  15. Rakesh Bhatia · 2 shared papers, 2018–2021 · strength 0.22
  16. Haley L. Peters · 3 shared papers, 2012–2019 · strength 0.18
  17. Xiaoqi Li · 1 shared paper, 2022 · strength 0.17
  18. Poomy Pandey · 2 shared papers, 2015–2021 · strength 0.15
  19. Parthasarathy Seshacharyulu · 2 shared papers, 2015–2021 · strength 0.15
  20. Satyanarayana Rachagani · 2 shared papers, 2015–2021 · strength 0.15
  21. Andrew C. Cannon · 1 shared paper, 2021 · strength 0.15
  22. Christopher M. Thompson · 1 shared paper, 2021 · strength 0.15
  23. Jennifer D. Black · 1 shared paper, 2022 · strength 0.15
  24. Madeline T. Olson · 1 shared paper, 2022 · strength 0.15
  25. Ying Yan · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.